J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout

The lead drug from Johnson & Johnson’s $6.5 billion buyout of Momenta, now being tested in nearly 10 indications, has cleared a Phase II in a rare blood disorder.

J&J’s therapeutics unit Janssen was sparse on details but said the drug, nipocalimab, met the primary endpoint in the UNITY study. The majority of pregnant patients in the trial experienced a live birth at or after 32 weeks without requiring intrauterine transfusion, or IUT, the Big Pharma said on Monday.